This analysis evaluates-from a US payer's perspective-the economic impact of using rivaroxaban versus enoxaparin for thromboprophylaxis following total hip or knee replacement surgery.
Brahim K. Bookhart, MBA, MPH
Advertisement
Articles by Brahim K. Bookhart, MBA, MPH
Advertisement
Latest Updated Articles
- Economic Model Comparing Rivaroxaban and Enoxaparin for Post-Orthopedic VTE Prophylaxis
Published: June 6th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Multifaceted Approach to Navigating Career Transitions in Pharmacy
2
First FDA-Approved Oral Liquid Sitagliptin for Adults with Type 2 Diabetes
3
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
4
Oxaliplatin as Part of Sequential Chemotherapy Shows Promise in Metastatic Pancreatic Cancer
5
